

TABLE OF CONTENTS

APPROVAL PAGE	ii
AUTHENTICITY STATEMENT	iii
PREFACE	iv
TABLE OF CONTENTS	v
LIST OF TABLES	vii
LIST OF FIGURES	viii
LIST OF SYMBOLS AND ABBREVIATION	ix
ABSTRACT	x
ABSTRAK	xi
CHAPTER I INTRODUCTION	1
A. Research Background	1
B. Research Questions	4
C. Research Objectives	4
D. Research Authenticity	5
E. Research Benefits	8
CHAPTER II BIBLIOGRAPHIC REVIEW	10
A. Literature Review	10
B. Theoretical Framework	50
C. Conceptual Framework	51
CHAPTER III RESEARCH METODOLOGY	52

A. Research Design.....	52
B. Place and Time of Research.....	52
C. Operational Definition	52
D. Subject and Population	53
E. Research Procedure.....	54
F. Timetable	56
G. Dummy Table	56
CHAPTER IV RESULTS AND DISCUSSION	58
A. Results.....	58
B. Discussion.....	68
C. Study Limitation	78
CHAPTER V CONCLUSION AND SUGGESTION	80
A. Conclusion	80
B. Recommendation	81
REFERENCES	82
APPENDICES	89

LIST OF TABLES

Table 1. List of previous research.....	5
Table 2. Drug Regimen for Tuberculosis	45
Table 3. WHO Treatment guidelines for multi-drug and rifampicin-resistant tuberculosis, 2018	46
Table 4. Timetable	56
Table 5. Antibiotic Susceptibility Pattern (Based on Resistance) of MDR-TB Isolates during 2013-2017 in Yogyakarta.....	58
Table 6. Antibiotic Susceptibility Pattern (Based on Resistance) per year of MDR- TB Isolates during 2013-2017 in Yogyakarta.....	59
Table 7. Antibiotic Susceptibility of Pattern of MDR-TB Isolates during 2013- 2017 in Yogyakarta.....	61
Table 8. Antibiotic Susceptibility Pattern per year of MDR-TB Isolates during 2013-2017 in Yogyakarta	61
Table 9. MDR-TB Isolates Patient's Characteristic Based on Gender, Age, Residency and Type Of Specimen during 2013-2017 in Yogyakarta	63

LIST OF FIGURES

Figure 1. Gender Per Year of Antibiotic Susceptible MDR-TB Isolates in Yogyakarta during 2013-2017	64
Figure 2. Age Per Year of Antibiotic Susceptible MDR-TB Isolates in Yogyakarta during 2013-2017.....	65
Figure 3. Residency Per Year of Antibiotic Susceptible MDR-TB Isolates in Yogyakarta during 2013-2017	66
Figure 4. Type of Specimen Per Year of Antibiotic Susceptible MDR-TB Isolates in Yogyakarta during 2013-2017	67

LIST OF SYMBOLS AND ABBREVIATION

SYMBOL

cm	Centimeter
mL	Mililiter
mm	Milimeter
>	More than
%	Percent

ABBREVIATION

AFB	Acid Fast bacteria
BCG	Bacille Calmett Guerin
CD4	Cluster of Differentiation 4
CO ₂	Carbon dioxide
DM	Diabetes Mellitus
DNA	Deoxyribonucleic Acid
DR-TB	Drug-Resistance Tuberculosis
DST	Drug Susceptibility Test
FDA	Food and Drug Administration
H ₂ SO ₄	Sulfuric Acid
HCl	Hydrochloride Acid
HIV	Human Immunodeficiency Virus
IFN-γ	Interferon Gamma
IGRAs	Interferon-Gamma Release Assays
inhA	Inhibin Alpha Subunit
KatG	Mycobacterium tuberculosis catalase-peroxidase
LJ	Lowenstein-Jensen
LPA	Line Probe Assay
MTB	<i>Micobacterium tuberculosis</i>
MDR-TB	Multi-Drug Resistance-Tuberculosis
NAA	Nucleic Acid Amplification
OADC	Oleic acid, Albumin, Dextrose and Catalase
PCR	Polymerase Chain Reaction
PPD	Purified Protein Derivative
RNA	Ribonucleic Acid
rpoB	DNA-directed RNA polymerase subunit beta
RR	Rifampicin-Resistance
SIRE	Streptomycin Isoniazid Rifampicin Ethambutol
TB	Tuberculosis
XDR-TB	Extensive-Drug Resistance Tuberculosis